RxDoctor Payments Data

Mark Strosser, OD

Optometrist · St Petersburg, FLNPI 1902800683

Payments from drug & device makers

$4,313in general payments, 2019–2025

Across 58 payments — averaging $74.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$565
  • Coopervision Inc.$523
  • Amgen$512
  • Alcon$492
  • Tarsus Pharmaceuticals, Inc.$468
  • AbbVie$378
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,313 in reported general payments places this provider in the 85th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$123,103
Medicare patients
717
Services billed
1,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate20$18,678
LumiganBimatoprost33$15,180
SimbrinzaBrinzolamide/Brimonidine Tart11$3,862
Loteprednol Etabonate23$2,449
Latanoprost206$2,445
Brimonidine Tartrate12$2,161
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$853
Doxycycline Hyclate11$805
Prednisolone Acetate26$730
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha56$591
Dorzolamide Hcl20$451
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$447
Timolol Maleate31$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$56$18,67820 claims
AbbVieLumigan$378$15,18033 claims
AlconSimbrinza$492$3,86211 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$22$2,44923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,166 optometrist providers in Florida.

Other optometrist in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →